Amisulpride has been shown to be as effective as first-generation antipsychotics 11 and other second-generation antipsychotics 12 in the treatment of acute exacerbations of schizophrenia. A significant effect on negative symptoms has also been reported, particularly at lower doses. 13 The purpose of this study was to examine the efficacy of augmenting clozapine treatment with amisulpride in a cohort of subjects with clozapine-resistant schizophrenia. The rationale for using amisulpride as add-on lies in its unique receptor profile allowing it to be regarded as a particularly advantageous addon drug in combination with a multireceptor substance such as clozapine, as additive effects only appear in terms of dopamine receptors and not in terms of muscarinergic, adrenergic or histaminergic receptors where addition would just lead to an increased side-effect burden.
Method
Study participants were a random sample of 20 subjects with over a trial period of at least 6 weeks. Treatment with both these medications had to be at a dosage equivalent to at least 10 mg haloperidol per day or had to have been discontinued because of intolerable side-effects, after which clozapine was initiated. To be considered for the trial, the daily dosage of clozapine had to be at least 400 mg/day, or the maximum tolerated dose, for at least 6 weeks. Furthermore, no change in dose of any medication was allowed for 6 weeks before inclusion. Clozapine treatmentresistant psychosis was defined as a score of at least 4 on at least 1 item of the positive subscale of the Positive and Negative Syndrome Scale (PANSS).
14 Exclusion criteria were: (i) subjects not stabilised on their current treatment, i.e. subjects who were considered to be still improving/deteriorating on treatment with clozapine; and
(ii) subjects with unstable neurological or physical disease.
All the patients had been inpatients for at least 10 weeks before inclusion in the study and there was no history of current substance abuse or dependence. All ratings were done by a single, blinded rater (AS). AS took no part in the treatment of the subjects before or during the trial and was not aware of the dose of amisulpride that subjects received. Baseline demographic data were obtained and all subjects were rated using the PANSS. Although no fixed dose of amisulpride was defined in the protocol, in the event all subjects were titrated to 400 mg amisulpride within 3 days, after which the dose remained constant for the rest of the treatment period. AS was unaware of the fact that all subjects were receiving the same dose of adjunctive amisulpiride. Subjects were re-evaluated at 8 weeks using the same scales.
Statistical analysis
All analyses were performed using Statistica 6 software (StatSoft Inc. 1994 -2003). As subjects only had two evaluations (baseline and endpoint), we did not use the last observation carried forward, but did a completers-only analysis. As it turned out, only 1 subject did not complete the study. The paired t-test was used to determine the significance of changes in continuous variables over the study period. Spearman's rank-order correlation coefficients were calculated to determine possible correlations between changes in continuous variables. Significance tests were performed at an alpha level of 0.05.
Results
Twenty subjects were included in the study. Eighteen subjects (90%) were male. The mean age at inclusion (± standard deviation (SD)) was 37. Table I . To further explore the change in the general psychopathology subscale and the effect of mood symptoms, we also evaluated the change in the PANSS depression factor, as described by Kay in his original factor analysis of the PANSS, 15 as well as the change in the general psychopathology subscale where the items of the depression factor (G1, G2, G3 and G6)
were removed. Results are listed in Table II .
Because the most significant changes were in the depression factor and the negative symptom subscale, we were interested to explore the possibilty that these were in fact reflecting the same changes, The finding on the effect on the depression factor is similar to the results of a recent meta-analysis of the use of amisulpride in acute exacerbations of schizophrenia. 16 Our study suggests that these effects are also achievable in patients regarded as treatment-resistant. There have been conflicting reports regarding the relationship between depressive symptoms and treatment outcome. However, it would appear that the presence of depressive symptoms in the acute phase of the illness might be associated with a favourable outcome. 17 However, if these symptoms persist they appear appear to be negative prognostic indicators. 18 It is clear, therefore, that treatment strategies in schizophrenia should always consider mood symptoms as an important focus of treatment.
The differentiation between primary and secondary negative symptoms continues to be a major challenge to researchers and 19 Although it would be premature to claim that the effect we saw was the result of an effect on 'core' negative symptoms, we can say with some degree of conviction that it was
clearly not a result of improvement in mood symptoms. We did not formally record assessments of extrapyramidal side-effects, but it seems highly unlikely that the improvement we saw would have resulted from improvement in these side-effects. Further studies are needed to elucidate the effect of amisulpride on negative symptoms.
This study has a number of limitations. As it was a naturalistic pilot study, no control group was included and the number of subjects was small. However, there was only 1 dropout. Furthermore, a number of subjects were receiving concomitant medications, but it is important to note that with regard to ongoing medication no changes in dosage were made for at least 8 weeks before inclusion or at any time during the study. The treatment period was also fairly short, but this compared well with the treatment period in the study by Shiloh et al. 9 Although the study results are fairly modest, there was a clear statistically significant improvement from baseline. Furthermore, it must be remembered that our study population was severely treatment-resistant. Also, the relatively low dose of amisulpride may have limited its effect on positive symptoms. However, this study does suggest that a novel antipsychotic, amisulpride, deserves attention as add-on medication in treatment-resistant populations.
